Skjul metadata

dc.date.accessioned2023-03-27T15:21:49Z
dc.date.available2023-04-27T22:46:01Z
dc.date.created2022-10-13T09:50:40Z
dc.date.issued2022
dc.identifier.citationBretthauer, Michael Løberg, Magnus Wieszczy, Paulina Kalager, Mette Emilsson, Louise Garborg, Kjetil Kjeldstad Rupinski, Maciej Dekker, Evelien Spaander, Manon Bugajski, Marek Holme, Øyvind Zauber, Ann G. Pilonis, Nastazja D. Mróz, Andrzej Kuipers, Ernst J. Shi, Joy Hernán, Miguel A. Adami, Hans Olov Regula, Jaroslaw Hoff, Geir Kamiński, Michał Filip . Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. New England Journal of Medicine. 2022, 387(17), 1547-1556
dc.identifier.urihttp://hdl.handle.net/10852/101829
dc.description.abstractBackground: Although colonoscopy is widely used as a screening test to detect colorectal cancer, its effect on the risks of colorectal cancer and related death is unclear. Methods: We performed a pragmatic, randomized trial involving presumptively healthy men and women 55 to 64 years of age drawn from population registries in Poland, Norway, Sweden, and the Netherlands between 2009 and 2014. The participants were randomly assigned in a 1:2 ratio to either receive an invitation to undergo a single screening colonoscopy (the invited group) or to receive no invitation or screening (the usual-care group). The primary end points were the risks of colorectal cancer and related death, and the secondary end point was death from any cause. Results: Follow-up data were available for 84,585 participants in Poland, Norway, and Sweden - 28,220 in the invited group, 11,843 of whom (42.0%) underwent screening, and 56,365 in the usual-care group. A total of 15 participants had major bleeding after polyp removal. No perforations or screening-related deaths occurred within 30 days after colonoscopy. During a median follow-up of 10 years, 259 cases of colorectal cancer were diagnosed in the invited group as compared with 622 cases in the usual-care group. In intention-to-screen analyses, the risk of colorectal cancer at 10 years was 0.98% in the invited group and 1.20% in the usual-care group, a risk reduction of 18% (risk ratio, 0.82; 95% confidence interval [CI], 0.70 to 0.93). The risk of death from colorectal cancer was 0.28% in the invited group and 0.31% in the usual-care group (risk ratio, 0.90; 95% CI, 0.64 to 1.16). The number needed to invite to undergo screening to prevent one case of colorectal cancer was 455 (95% CI, 270 to 1429). The risk of death from any cause was 11.03% in the invited group and 11.04% in the usual-care group (risk ratio, 0.99; 95% CI, 0.96 to 1.04). Conclusions: In this randomized trial, the risk of colorectal cancer at 10 years was lower among participants who were invited to undergo screening colonoscopy than among those who were assigned to no screening. (Funded by the Research Council of Norway and others; NordICC ClinicalTrials.gov number, NCT00883792.).
dc.description.abstractEffect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death
dc.languageEN
dc.titleEffect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death
dc.title.alternativeENEngelskEnglishEffect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death
dc.typeJournal article
dc.creator.authorBretthauer, Michael
dc.creator.authorLøberg, Magnus
dc.creator.authorWieszczy, Paulina
dc.creator.authorKalager, Mette
dc.creator.authorEmilsson, Louise
dc.creator.authorGarborg, Kjetil Kjeldstad
dc.creator.authorRupinski, Maciej
dc.creator.authorDekker, Evelien
dc.creator.authorSpaander, Manon
dc.creator.authorBugajski, Marek
dc.creator.authorHolme, Øyvind
dc.creator.authorZauber, Ann G.
dc.creator.authorPilonis, Nastazja D.
dc.creator.authorMróz, Andrzej
dc.creator.authorKuipers, Ernst J.
dc.creator.authorShi, Joy
dc.creator.authorHernán, Miguel A.
dc.creator.authorAdami, Hans Olov
dc.creator.authorRegula, Jaroslaw
dc.creator.authorHoff, Geir
dc.creator.authorKamiński, Michał Filip
cristin.unitcode185,52,11,0
cristin.unitnameAvdeling for helseledelse og helseøkonomi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin2061038
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=New England Journal of Medicine&rft.volume=387&rft.spage=1547&rft.date=2022
dc.identifier.jtitleNew England Journal of Medicine
dc.identifier.volume387
dc.identifier.issue17
dc.identifier.startpage1547
dc.identifier.endpage1556
dc.identifier.doihttps://doi.org/10.1056/NEJMoa2208375
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0028-4793
dc.type.versionPublishedVersion


Tilhørende fil(er)

Finnes i følgende samling

Skjul metadata